

# Nabil M Ahmed

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2865665/publications.pdf>

Version: 2024-02-01

70  
papers

8,214  
citations

147566

31  
h-index

98622

67  
g-index

75  
all docs

75  
docs citations

75  
times ranked

11193  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. <i>Blood</i> , 2022, 140, 16-24.	0.6	14
2	CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression. <i>Leukemia</i> , 2021, 35, 75-89.	3.3	107
3	Targeting hydrogen sulphide signaling in breast cancer. <i>Journal of Advanced Research</i> , 2021, 27, 177-190.	4.4	46
4	Immunogenicity of CAR T cells in cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 379-393.	12.5	128
5	A subset of cytotoxic effector memory T cells enhances CAR T cell efficacy in a model of pancreatic ductal adenocarcinoma. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	12
6	CAR T-Cell Therapy for CNS Malignancies. , 2020, , 165-198.		0
7	Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. <i>Nature Communications</i> , 2020, 11, 3549.	5.8	103
8	Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. <i>Nature Medicine</i> , 2020, 26, 720-731.	15.2	141
9	Modulation of inhibitory signals in CAR T cells leads to improved activity against glioblastoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3031-3031.	0.8	0
10	Immunotherapy for pediatric brain tumors: past and present. <i>Neuro-Oncology</i> , 2019, 21, 1226-1238.	0.6	32
11	IMMU-05. COMBINATIONAL CAR T-CELL AND EPIGENETIC MODIFIER THERAPY TO TARGET POSTERIOR FOSSA TUMORS. <i>Neuro-Oncology</i> , 2019, 21, ii93-ii94.	0.6	1
12	Insights into pediatric rhabdomyosarcoma research: Challenges and goals. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27869.	0.8	57
13	Tandem CAR T cells targeting HER2 and IL13R $\pm$ 2 mitigate tumor antigen escape. <i>Journal of Clinical Investigation</i> , 2019, 129, 3464-3464.	3.9	20
14	Cell Adhesion of ALL to Stromal Cells May Mediate CAR T-Cell Resistance: A Novel Escape Mechanism for Immunotherapy. <i>Blood</i> , 2019, 134, 2623-2623.	0.6	0
15	CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. <i>Cancer</i> , 2018, 124, 2607-2620.	2.0	73
16	High Incidence of Autoimmune Disease after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1643-1650.	2.0	24
17	Current Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphocytic Leukemia: Success, Failure and Future Perspectivesâ€”A Single-Center Experience, 2008 to 2016. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1424-1431.	2.0	15
18	Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 506-518.	0.6	306

#	ARTICLE	IF	CITATIONS
19	TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2018, 78, 489-500.	0.4	122
20	Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 537-541.	2.0	21
21	A homing system targets therapeutic T cells to brain cancer. <i>Nature</i> , 2018, 561, 331-337.	13.7	36
22	Response to the comment on "Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma" by Bielamowicz et al. <i>Neuro-Oncology</i> , 2018, 20, 1004-1005.	0.6	4
23	Targeting CD19-negative relapsed B-acute lymphoblastic leukemia using trivalent CAR T cells.. <i>Journal of Clinical Oncology</i> , 2018, 36, 121-121.	0.8	8
24	Identification of diverse astrocyte populations and their malignant analogs. <i>Nature Neuroscience</i> , 2017, 20, 396-405.	7.1	410
25	HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma. <i>JAMA Oncology</i> , 2017, 3, 1094.	3.4	608
26	LC3A Silencing Hinders Aggresome Vimentin Cage Clearance in Primary Choroid Plexus Carcinoma. <i>Scientific Reports</i> , 2017, 7, 8022.	1.6	15
27	Quantitative Imaging Approaches to Study the CAR Immunological Synapse. <i>Molecular Therapy</i> , 2017, 25, 1757-1768.	3.7	49
28	Expansion of HER2-CAR T cells after lymphodepletion and clinical responses in patients with advanced sarcoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10508-10508.	0.8	32
29	A cellular platform to enable targeted brain delivery of T cells to glioblastoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2053-2053.	0.8	3
30	Tandem CAR T cells targeting HER2 and IL13R $\pm$ 2 mitigate tumor antigen escape. <i>Journal of Clinical Investigation</i> , 2016, 126, 3036-3052.	3.9	515
31	Realism and pragmatism in developing an effective chimeric antigen receptor T-cell product for solid cancers. <i>Cytotherapy</i> , 2016, 18, 1382-1392.	0.3	8
32	Targeting the tumour profile using broad spectrum chimaeric antigen receptor T-cells. <i>Biochemical Society Transactions</i> , 2016, 44, 391-396.	1.6	12
33	Polystyrene microspheres enable 10-color compensation for immunophenotyping of primary human leukocytes. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2015, 87, 1038-1046.	1.1	10
34	The Evolution of T-cell Therapies for Solid Malignancies. <i>Clinical Cancer Research</i> , 2015, 21, 3384-3392.	3.2	71
35	Armed hunter killers: discerning the role of adoptive T-cell transfer for glioblastoma. <i>Immunotherapy</i> , 2015, 7, 481-485.	1.0	5
36	Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 1688-1696.	0.8	778

#	ARTICLE	IF	CITATIONS
37	Is CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2015, 125, 307-315.	1.4	24
38	Cellular immunotherapy for pediatric solid tumors. <i>Cytotherapy</i> , 2015, 17, 3-17.	0.3	15
39	Safety of Multiple Doses of CAR T Cells. <i>Blood</i> , 2015, 126, 4425-4425.	0.6	5
40	Matched Unrelated Allogeneic Stem Cell Transplantation for Patients with Congenital Amegakaryocytic Thrombocytopenia: Texas Children's Hospital Experience. <i>Blood</i> , 2015, 126, 5529-5529.	0.6	0
41	Human Cytomegalovirus Antigens in Malignant Gliomas as Targets for Adoptive Cellular Therapy. <i>Frontiers in Oncology</i> , 2014, 4, 338.	1.3	10
42	Current concepts in the diagnosis and management of cytokine release syndrome. <i>Blood</i> , 2014, 124, 188-195.	0.6	2,080
43	Gene Therapy: Charting a Future Course—Summary of a National Institutes of Health Workshop, April 12, 2013. <i>Human Gene Therapy</i> , 2014, 25, 488-497.	1.4	12
44	Overexpression and constitutive nuclear localization of cohesin protease Separase protein correlates with high incidence of relapse and reduced overall survival in glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2014, 119, 27-35.	1.4	24
45	T cells redirected to interleukin-13R $\alpha$ 2 with interleukin-13 mutein—chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13R $\alpha$ 1. <i>Cytotherapy</i> , 2014, 16, 1121-1131.	0.3	68
46	Genetic modification of T cells with a novel bispecific chimeric antigen receptor to enhance the control of high-grade glioma (HGG).. <i>Journal of Clinical Oncology</i> , 2014, 32, 10027-10027.	0.8	7
47	Novel approaches and mechanisms of immunotherapy for glioblastoma. <i>Discovery Medicine</i> , 2014, 17, 145-54.	0.5	15
48	Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells. <i>Clinical Immunology</i> , 2013, 149, 55-64.	1.4	53
49	T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma. <i>Molecular Therapy</i> , 2013, 21, 629-637.	3.7	200
50	Adoptive Cell Therapies for Glioblastoma. <i>Frontiers in Oncology</i> , 2013, 3, 275.	1.3	47
51	The miR-223/Nuclear Factor I-A Axis Regulates Glial Precursor Proliferation and Tumorigenesis in the CNS. <i>Journal of Neuroscience</i> , 2013, 33, 13560-13568.	1.7	51
52	Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma. <i>Molecular Therapy</i> , 2013, 21, 2087-2101.	3.7	300
53	TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy. <i>Molecular Therapy - Nucleic Acids</i> , 2013, 2, e105.	2.3	371
54	Medulloblastoma—Biology and Microenvironment: A Review. <i>Pediatric Hematology and Oncology</i> , 2012, 29, 495-506.	0.3	10

#	ARTICLE	IF	CITATIONS
55	Generation of Polyclonal CMV-specific T Cells for the Adoptive Immunotherapy of Glioblastoma. <i>Journal of Immunotherapy</i> , 2012, 35, 159-168.	1.2	59
56	Nanoshell-mediated photothermal therapy improves survival in a murine glioma model. <i>Journal of Neuro-Oncology</i> , 2011, 104, 55-63.	1.4	127
57	PiggyBac-mediated Cancer Immunotherapy Using EBV-specific Cytotoxic T-cells Expressing HER2-specific Chimeric Antigen Receptor. <i>Molecular Therapy</i> , 2011, 19, 2133-2143.	3.7	110
58	Crosstalk between Medulloblastoma Cells and Endothelium Triggers a Strong Chemotactic Signal Recruiting T Lymphocytes to the Tumor Microenvironment. <i>PLoS ONE</i> , 2011, 6, e20267.	1.1	26
59	A Simple and Sensitive Method for Measuring Tumor-Specific T Cell Cytotoxicity. <i>PLoS ONE</i> , 2010, 5, e11867.	1.1	66
60	Glioma Cells Display Complex Cell Surface Topographies That Resist the Actions of Cytolytic Effector Lymphocytes. <i>Journal of Immunology</i> , 2010, 185, 4793-4803.	0.4	26
61	HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors. <i>Clinical Cancer Research</i> , 2010, 16, 474-485.	3.2	324
62	Immunotherapy for Pediatric Central Nervous System Tumors. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, S75-S81.	2.0	0
63	T-cell-based Therapies for Malignancy and Infection in Childhood. <i>Pediatric Clinics of North America</i> , 2010, 57, 83-96.	0.9	5
64	Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression. <i>Molecular Therapy</i> , 2009, 17, 1779-1787.	3.7	171
65	How to design effective vaccines: lessons from an old success story. <i>Expert Review of Vaccines</i> , 2009, 8, 543-546.	2.0	16
66	Successful Treatment of Stem Cell Graft Failure in Pediatric Patients Using a Submyeloablative Regimen of Campath-1H and Fludarabine. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1298-1304.	2.0	21
67	Regression of Experimental Medulloblastoma following Transfer of HER2-Specific T Cells. <i>Cancer Research</i> , 2007, 67, 5957-5964.	0.4	153
68	Acute Hepatic Sequestration Associated With Pneumococcal Infection in a 5-year-old Boy With Sickle $\beta^0$ -thalassemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2007, 29, 720-724.	0.3	9
69	Viral lymphomagenesis. <i>Current Opinion in Hematology</i> , 2006, 13, 254-259.	1.2	10
70	Genetically Modified Her2-Specific T Cells Recognize Low and High Her2 Expressing Breast Cancer Cells. <i>Blood</i> , 2005, 106, 5540-5540.	0.6	0